ID: MRFR/Pharma/4609-HCR | February 2021 | Region: Global | 100 pages
The global porokeratosis treatment market is segmented
on the basis of type of porokeratosis, diagnosis and treatment, and end-user.
By type of porokeratosis, the market is classified as Disseminated Actinic Porokeratosis (DSAP), linear porokeratosis, porokeratosis of mantoux, Porokeratotic Eccrine Ostial and Dermal Duct Nevus (PEODDN), and punctate porokeratosis.
Based on diagnosis and treatment, the market is classified as diagnosis and treatment. The diagnosis segment is further classified as biopsy, differential diagnosis, and others. The sub-segments of differential diagnosis include squamous cell carcinoma, lichenoid keratosis, and epidermal nevus. The treatment segment is further classified as topical diclofenac, ingenol mebutate, topical vitamin D analog, 5-Fluorouracil, immunomodulators, photodynamic therapy, retinoids, cryotherapy, lasers, immunosuppressive agents, and others. The sub-segments of immunomodulators include imiquimod and resiquimod. The sub-segments of retinoids include topical retinoids and oral retinoids. The sub-segments of immunosuppressive agents include calcineurin inhibitors and others.
By end-user, the market is classified as hospitals and clinics, diagnostic centers, drug stores, research and academic institutes, and others.
Geographically, the global porokeratosis treatment market has been segmented into America, Europe, Asia Pacific, and the Middle East and Africa. The American porokeratosis treatment market is further segmented into North America and South America. North America is further classified as the U.S. and Canada.
The European porokeratosis treatment market is segmented into Western Europe and Eastern Europe. Western Europe is further classified as Germany, France, the U.K., Italy, Spain, and the Rest of Western Europe.
The Asia Pacific porokeratosis treatment market is segmented into Japan, China, India, the Republic of Korea, Australia, and the Rest of Asia Pacific.
The Middle Eastern and African porokeratosis treatment market is segmented into the Middle East and Africa.
Regional Market Summary
Global Porokeratosis Treatment Market Share, by Region, 2017 (%)
Source: MRFR Analysis
The Americas dominates the porokeratosis treatment market owing to the rising prevalence of disseminated superficial actinic porokeratosis and increasing renal transplant cases, as around 10.68% of renal transplant recipients suffered from porokeratosis. According to the National Kidney Foundation, Inc., in 2014, 17,107 kidney transplants took place in the U.S. Moreover, advanced diagnostic and therapeutic solutions, high healthcare expenditure, and the presence of leading players are expected to boost the American porokeratosis treatment market.
Europe holds the second position in the porokeratosis treatment market. It is expected that the rising contribution of various marketers is likely to drive the European porokeratosis treatment market. For instance, in July 2016, Chugai and Galderma announced the global license agreement for the development and marketing of Nemolizumab worldwide. The Nemolizumab is a novel biologic for skin diseases.
Asia Pacific is the fastest growing porokeratosis treatment market owing to a huge patient pool, increasing demand for treatment, and rising healthcare expenditure. In this region, the Mibelli type is most frequent as compared to other types. In Singapore, the Mibelli type of porokeratosis was present in 56% of the porokeratosis patients in 2013, suggested by a study published in the Cases in Dermatology Journal.
The Middle East and Africa holds the lowest share of the global porokeratosis treatment market due to the presence of poor and slow developing countries, especially, in the African region.
Market Research Future research is conducted by industry experts who offer insight into industry structure, market segmentation, treatment assessment, Competitive Landscape (CL), penetration, as well as on emerging trends. Besides primary interviews (~ 80%) and secondary research (~ 20%), their analysis is based on their years of professional expertise in respective industries. Our analysts also predict where the market will be headed in the next five to ten years, by analyzing historical trends and current market positions. Furthermore, the varying trends of segments and categories geographically presented are studied and are estimated based on the primary and secondary research.
The extensive primary research was conducted to gain a deeper insight of the market and the industry performance. In this particular report, we have conducted primary surveys (interviews) with the key level executives (VPs, CEOs, Marketing Directors, Business Development Managers, and many more) of the major players who are active in the market. In addition to analyzing the current and historical trends, our analysts predict where the market is headed, over the next five to ten years.
Secondary research was mainly used to collect and identify information useful for an extensive, technical, market-oriented, and commercial study of the porokeratosis treatment market. It was also used to obtain key information about major players, market classification and segmentation according to industry trends, geographical markets, and developments related to the market and treatment perspectives. For this study, analysts have gathered information from various credible sources, such as annual reports, SEC filings, journals, white papers, corporate presentations, company websites, the international organization of chemical manufacturers, some paid databases, and many others.
Global Porokeratosis Treatment Market, by Type
Global Porokeratosis Treatment Market, by Diagnosis & Treatment
Global Porokeratosis Treatment Market, by End-User
Global Porokeratosis Treatment Market, by Region
|Market Size||Significant Value|
|Forecast Units||Value (USD Million)|
|Report Coverage||Revenue Forecast, Competitive Landscape, Growth Factors, and Trends|
|Segments Covered||Type, Diagnostic and Treatment, End User|
|Geographies Covered||North America, Europe, Asia-Pacific, and Rest of the World (RoW)|
|Key Vendors||Angiodynamics, Inc. (U.S.), Allergan (Republic of Ireland), Alma Lasers (Israel), Beiersdorf AG (Germany), Biogen (U.S.), Biolase Inc. (U.S.), Coherent, Inc. (U.S.), Coty Inc. (U.S.), Cutera (U.S.), Danaher Corporation (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), Hologic Inc. (U.S.), IPG Photonics Corporation (U.S.), IRIDEX Corp. (U.S.), L’Oreal (France), Lumenis (U.S.), Pfizer (U.S.), PhotoMedex, Inc. (U.S.), Valeant Pharmaceuticals (Canada), and others.|
|Key Market Opportunities||
|Key Market Drivers||The rising number of renal transplants|
Frequently Asked Questions (FAQ) :
Porokeratosis is a rare skin condition presenting as small, round patches on the skin. In a small number of cases, these patches may develop into skin cancer.
Global Porokeratosis Market is expected to exhibit a strong 6% CAGR over the forecast period from 2018 to 2027.
The rising number of renal transplants is the major driver for the porokeratosis market.
The Americas dominate the global Porokeratosis Market.
Leading players in the Porokeratosis Market include Alma Lasers, Coherent Inc., and Biogen, among others.